Table 2.
Median SARS-CoV-2 antibody levels stratified after the occurrence of adverse effects.
| Type of Adverse Effect | SARS-CoV-2 Antibody Assay |
Subjects with Adverse Events after Prime Dose |
p-Value | Subjects with Adverse Events after Boost Dose |
p-Value | ||
|---|---|---|---|---|---|---|---|
| yes | no | yes | no | ||||
| any adverse effect | Vircell-IgG (AI) | 22.3 | 17.2 | 0.167 | 21.5 | 21.4 | 0.147 |
| DiaSorin-IgG (AU/mL) | 1060 | 1000 | 0.116 | 1020 | 1011 | 0.625 | |
| YHLO-Nab (AU/mL) | 2451 | 2526 | 0.519 | 2555 | 1991 | 0.421 | |
| inability to work | Vircell-IgG (AI) | 15.2 | 21.7 | 0.448 | 23.5 | 21.5 | 0.158 |
| DiaSorin-IgG (AU/mL) | 1016 | 986 | 0.619 | 1060 | 1011 | 0.660 | |
| YHLO-Nab (AU/mL) | 1245 | 2587 | 0.051 | 2305 | 2583 | 0.856 | |
| any local injection site reactions | Vircell-IgG (AI) | 21.9 | 19.0 | 0.670 | 19.6 | 22.2 | 0.611 |
| DiaSorin-IgG (AU/mL) | 1035 | 1010 | 0.439 | 1015 | 1021 | 0.955 | |
| YHLO-Nab (AU/mL) | 2350 | 2592 | 0.709 | 2583 | 1866 | 0.450 | |
| pain | Vircell-IgG (AI) | 20.8 | 20.3 | 0.813 | 19.6 | 22.2 | 0.754 |
| DiaSorin-IgG (AU/mL) | 1020 | 1011 | 0.803 | 1015 | 1021 | 0.913 | |
| YHLO-Nab (AU/mL) | 2423 | 2558 | 0.951 | 2590 | 1601 | 0.171 | |
| swelling | Vircell-IgG (AI) | 22.4 | 20.1 | 0.319 | 20.1 | 21.9 | 0.955 |
| DiaSorin-IgG (AU/mL) | 1060 | 1011 | 0.675 | 1000 | 1020 | 0.796 | |
| YHLO-Nab (AU/mL) | 2874 | 2451 | 0.925 | 3377 | 2381 | 0.371 | |
| redness | Vircell-IgG (AI) | 11.4 | 21.4 | 0.985 | 11.4 | 21.9 | 0.196 |
| DiaSorin-IgG (AU/mL) | 921 | 1020 | 0.937 | 903 | 1020 | 0.370 | |
| YHLO-Nab (AU/mL) | 2793 | 2451 | 0.992 | 2793 | 2395 | 0.637 | |
| local lymphadenopathy | Vircell-IgG (AI) | --- | --- | --- | 29.1 | 18.9 | 0.163 |
| DiaSorin-IgG (AU/mL) | --- | --- | --- | 1220 | 1000 | 0.041 | |
| YHLO-Nab (AU/mL) | --- | --- | --- | 2795 | 2461 | 0.659 | |
| any systemic reactions | Vircell-IgG (AI) | 26.7 | 16.1 | 0.037 | 22.4 | 13.5 | 0.015 |
| DiaSorin-IgG (AU/mL) | 1255 | 958 | 0.014 | 1060 | 943 | 0.109 | |
| YHLO-Nab (AU/mL) | 2730 | 2345 | 0.189 | 2583 | 2381 | 0.189 | |
| chills | Vircell-IgG (AI) | --- | --- | --- | 28.2 | 20.3 | 0.147 |
| DiaSorin-IgG (AU/mL) | --- | --- | --- | 1185 | 1000 | 0.050 | |
| YHLO-Nab (AU/mL) | --- | --- | --- | 2702 | 2395 | 0.471 | |
| malaise | Vircell-IgG (AI) | 29.1 | 20.1 | 0.311 | 29.1 | 18.6 | 0.027 |
| DiaSorin-IgG (AU/mL) | 1330 | 1011 | 0.370 | 1100 | 1010 | 0.318 | |
| YHLO-Nab (AU/mL) | 1460 | 2526 | 0.976 | 2416 | 2517 | 0.983 | |
| nausea | Vircell-IgG (AI) | --- | --- | --- | 29.9 | 20.1 | 0.289 |
| DiaSorin-IgG (AU/mL) | --- | --- | --- | 1310 | 1010 | 0.036 | |
| YHLO-Nab (AU/mL) | --- | --- | --- | 2558 | 2489 | 0.593 | |
| fatigue | Vircell-IgG (AI) | 28.4 | 18.9 | 0.171 | 22.4 | 15.1 | 0.039 |
| DiaSorin-IgG (AU/mL) | 1250 | 1010 | 0.490 | 1050 | 958 | 0.257 | |
| YHLO-Nab (AU/mL) | 1601 | 2526 | 0.863 | 2526 | 2395 | 0.599 | |
| headache | Vircell-IgG (AI) | 26.9 | 17.9 | 0.042 | 22.2 | 21.4 | 0.152 |
| DiaSorin-IgG (AU/mL) | 1310 | 1005 | 0.011 | 1020 | 1010 | 0.339 | |
| YHLO-Nab (AU/mL) | 6689 | 2345 | 0.062 | 2650 | 2381 | 0.443 | |
| pain in the limbs | Vircell-IgG (AI) | --- | --- | --- | 22.5 | 21.4 | 0.217 |
| DiaSorin-IgG (AU/mL) | --- | --- | --- | 1110 | 1000 | 0.395 | |
| YHLO-Nab (AU/mL) | --- | --- | --- | 2788 | 2343 | 0.370 | |
| joint pain | Vircell-IgG (AI) | --- | --- | --- | 20.1 | 21.5 | 0.847 |
| DiaSorin-IgG (AU/mL) | --- | --- | --- | 869 | 1020 | 0.158 | |
| YHLO-Nab (AU/mL) | --- | --- | --- | 1660 | 2526 | 0.652 | |
| muscle pain | Vircell-IgG (AI) | --- | --- | --- | 22.3 | 21.4 | 0.284 |
| DiaSorin-IgG (AU/mL) | --- | --- | --- | 1010 | 1020 | 0.965 | |
| YHLO-Nab (AU/mL) | --- | --- | --- | 2810 | 2451 | 0.926 | |
| elevated temperature | Vircell-IgG (AI) | --- | --- | --- | 26.8 | 21.4 | 0.548 |
| DiaSorin-IgG (AU/mL) | --- | --- | --- | 1050 | 1011 | 0.713 | |
| YHLO-Nab (AU/mL) | --- | --- | --- | 2197 | 2526 | 0.461 | |
Subjects with certain adverse effects have significantly higher mean antibody levels compared to subjects without these adverse effects using the Vircell-IgG and/or the DiaSorin-IgG assay but not with the Yhlo-NAb surrogate neutralization assay. Adverse effects that occurred in less than five subjects were excluded from the analysis. Significant results are highlighted in bold. AI, antibody index; AU, arbitrary units.